Szadejko Karol, Szabat Krzysztof, Ludwichowska Anna, Sławek Jarosław
Oddział Neurologii, 7 Szpital Marynarki Wojennej w Gdańsku-Oliwie.
Przegl Lek. 2013;70(7):443-7.
Homocysteine (Hcy) has recently become the focus of interest in the research on Parkinson's disease (PD) and other neurodegenarative disorders. Chronic treatment with levodopa (LD), considered the standard treatment for PD, leads to an increase in homocysteine concentration in serum and cerebro-spinal fluid. Independently from this effect, homocysteine is also regarded as a marker of neurodegenerative disorders. Main interest was focused on hyperhomocysteinemia (hHcy) as the potential risk factor for atheromatosis. Subsequently, its role in neuropsychiatric diseases, e.g. depression, mild cognitive impairment and dementia was investigated. The potential pathogenic role of Hcy in peripheral neuropathy in patients with PD that are treated with LD is an interesting hypothesis but the literature is scarce. Confirmation of this association may lead to introduction of preventive therapies, e.g. administration of vitamin B and inhibitors of catechol-O-methyl transferase (COMT) that may decrease the Hcy blood concentrations.
同型半胱氨酸（Hcy）最近已成为帕金森病（PD）及其他神经退行性疾病研究的关注焦点。左旋多巴（LD）是治疗PD的标准药物，长期使用会导致血清和脑脊液中的同型半胱氨酸浓度升高。抛开这一影响不谈，同型半胱氨酸也被视为神经退行性疾病的一个标志物。人们主要关注高同型半胱氨酸血症（hHcy）作为动脉粥样硬化潜在危险因素的情况。随后，对其在神经精神疾病（如抑郁症、轻度认知障碍和痴呆症）中的作用展开了研究。Hcy在接受LD治疗的PD患者周围神经病变中的潜在致病作用是一个有趣的假设，但相关文献较少。证实这种关联可能会促使引入预防性治疗方法，如使用维生素B和儿茶酚-O-甲基转移酶（COMT）抑制剂，这可能会降低血液中的Hcy浓度。
